KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials.

Tiffany Mayo, Jonathan I Silverberg, April Armstrong, Emma Guttman-Yassky, Andrew Blauvelt, Ben Esdaile, Kenji Kabashima, Melinda Gooderham, Leon Kircik, Shannon Schneider, Niels Bennike, Rie von Eyben, Britta C Martel, Mads A Røpke, Norito Katoh, Andrew F Alexis

Am J Clin Dermatol 27(1) 149-166

PMID41118053
PMCIDPMC12860764
DOI10.1007/s40257-025-00985-1
发表日期2025-10-21
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Fig. 4:森林图/亚组分析图;Fig. 5:森林图/亚组分析图;另有 1 张未列出。
摘要

摘要

BACKGROUND: Differences in atopic dermatitis (AD) prevalence, clinical presentation, and pathophysiology have been reported in different ethnic/racial groups; however, clinical trial data for patients with skin of color are limited. Tralokinumab is a monoclonal antibody that specifically targets interleukin-13, a key driver of AD. OBJECTIVES: To investigate the efficacy and safety of tralokinumab, and examine AD biomarker expression at baseline and week 16, by self-reported racial subgroup (Asian, Black, and White) in patients with moderate-to-severe AD. METHODS: Post hoc analyses were conducted by racial subgroup using data from four phase 3 trials: placebo-controlled parent trials ECZTRA 1, 2, and 3 and the open-label extension trial ECZTEND. Endpoints included Investigator's Global Assessment (IGA) 0/1, 75% improvement in Eczema Area and Severity Index (EASI-75), and adverse events. In ECZTRA 1, serum and skin samples were analyzed for biomarker expression by immunoassay and Staphylococcus aureus (S. aureus) abundance by quantitative polymerase chain reaction (qPCR). RESULTS: A total of 1876 patients pooled from ECZTRA 1/2/3 (Asian/Black/White N = 407/134/1335) and 1392 patients from ECZTEND (Asian/Black/White N = 203/108/1081) were included. Baseline characteristics were largely balanced between treatment groups and racial subgroups, although AD severity was more moderate in Black patients and regional differences were observed. At week 16 of ECZTRA 1/2/3, tralokinumab improved efficacy outcomes, including IGA 0/1 and EASI-75, relative to placebo across all subgroups. Further improvements beyond week 16 were observed with continued tralokinumab treatment, including 78%, 88%, and 83% of Asian, Black, and White patients, respectively, achieving EASI-75 at week 56 of ECZTEND (corresponding to up to 2 years total tralokinumab treatment). At baseline, serum biomarker levels were elevated in Asian patients from Japan compared with other subgroups, while Asian patients from USA/Europe had lower S. aureus abundance, when adjusting for IGA. The safety profile of tralokinumab was comparable to placebo, and serious adverse events and adverse events leading to treatment discontinuation were rare, across racial subgroups. CONCLUSIONS: Tralokinumab was well-tolerated and improved signs, symptoms, and biomarkers in patients with moderate-to-severe AD at 16 weeks across the racial subgroups studied, with further improvement in response rates up to 2 years of treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03131648 (registered 24 April 2017), NCT03160885 (registered 18 May 2017), NCT03363854 (registered 01 December 2017), and NCT03587805 (registered 03 July 2018).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Summary of tralokinumab clinical trials and subgroups included in the current analysis. A The efficacy and safety of tralokinumab treatment was analyzed by self-identified racial subgroup (Asian, Black, and White) in adults with moderate-to-severe AD in the ECZTRA 1, ECZTRA 2, and ECZTRA 3 parent trials. ECZTRA 1 and 2 were identically designed, multinational, double-blinded, randomized, placebo-controlled, 52-week trials of tralokinumab monotherapy. ECZTRA 3 was a multinational, double-blind, randomized, placebo-controlled, 32-week trial of tralokinumab plus TCS as needed. In ECZTRA 1 and 2, patients were randomized 3:1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks (Q2W) for 16 weeks following a 600 mg loading dose. Patients who achieved the primary endpoints (IGA 0/1 or EASI-75 at week 16) with tralokinumab were re-randomized 2:2:1 to tralokinumab Q2W or every 4 weeks (Q4W) or placebo for an additional 36 weeks; patients who did not were transferred to open-label tralokinumab Q2W plus optional TCS. For patients in blinded treatment arms, rescue treatment could be used at the discretion of the investigator to control intolerable symptoms. In ECZTRA 3, patients were randomized 2:1 to subcutaneous 300 mg of tralokinumab plus TCS as needed or placebo plus TCS as needed Q2W for 16 weeks following a 600 mg loading dose. Patients who achieved IGA 0/1 or EASI-75 at week 16 with tralokinumab were re-randomized to tralokinumab Q2W or Q4W, with TCS as needed, for an additional 16 weeks; patients who did not receive tralokinumab Q2W plus TCS as needed. Regarding the USPI versus total randomized population, two sites in ECZTRA 2 and one site in ECZTRA 3 were closed owing to Good Clinical Practice noncompliance issues. Patients who reported race other than Asian, Black, or White ( N = 66 in pooled ECZTRA 1/2/3) were not included in the current analysis. B ECZTEND interim analyses. ECZTEND ( NCT03587805 ) is an ongoing open-label extension trial assessing the safety and efficacy of tralokinumab over 5 years after the completion of parent trials. In ECZTEND, patients who completed parent trials of tralokinumab received 300 mg of tralokinumab Q2W (home use) after a 600 mg loading dose plus optional TCS or topical calcineurin inhibitor, with visits every 8 weeks. All patients who completed parent trials at sites with ECZTEND were eligible to enroll, regardless of prior treatment or response. The current analysis included adult patients who completed 56 weeks of tralokinumab in ECZTEND by 30 April 2021 data cutoff after completion of any of the following parent trials: ECZTRA 1, 2, 3, 4, 5, and 7. Patients who reported race other than Asian, Black, or White ( N = 38 in ECZTEND) were not included in the current analysis. AD atopic dermatitis, EASI Eczema Area and Severity Index, IGA Investigator's Global Assessment, N number of patients per group, TCS topical corticosteroids, USPI United States Prescribing Information
非 KM Figure
Fig. 2A Percentages of patients achieving EASI-75 and IGA 0/1 by racial subgroup at week 16 (pooled ECZTRA 1/2/3). B LS mean changes from baseline in EASI, worst pruritus NRS, POEM, and DLQI at week 16 (pooled ECZTRA 1/2/3). For A , percentage of responders listed above bars and number of responders out of number of patients with available data listed within bars. For B , error bars show standard errror and number of patients with available data listed within bars. Values rounded to nearest whole number. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. BL baseline, DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity Index, IGA Investigator's Global Assessment, LS least squares, NRS Numeric Rating Scale, POEM pPatient-Oriented Eczema Measure
非 KM Figure
Fig. 3Percentages of patients achieving EASI-75 and IGA 0/1 by racial subgroup at A week 52 (pooled ECZTRA 1/2) and B week 32 in the ECZTRA 3 TCS combination trial. In these analyses, all patients initially treated with tralokinumab were followed in a single group. For ECZTRA 1/2 analysis, patients re-randomized to placebo at week 16 were set to missing and imputed from the similar responder populations re-randomized to tralokinumab Q2W or Q4W at week 16 (see Methods section for details). Percentage of responders listed above bars and number of responders out of number of patients with available data listed within bars; values rounded to nearest whole number. EASI Eczema Area and Severity Index, IGA Investigator's Global Assessment, TCS topical corticosteroids
非 KM Figure
Fig. 4Percentages of patients by racial subgroup achieving A EASI-75 and IGA 0/1 and B worst weekly pruritus NRS ≤4 and DLQI ≤5 at week 56 in ECZTEND, corresponding to up to 2 years of tralokinumab treatment, as observed and after adjusting for baseline differences, including race and country as main effects. Percentage of responders listed above bars and number of responders out of number of patients with available data listed within bars for observed data. Adj adjusted, AO as observed, DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity Index, IGA Investigator's Global Assessment, NRS Numeric Rating Scale
非 KM Figure
Fig. 5Predicted means at baseline of A key serum biomarkers and B S. aureus abundance by SOC subgroup analyzed in a mixed effect model, including adjusting for baseline IGA, age, and sex (see Appendix S1 in the Supporting Information for additional details). Error bars show 95% confidence intervals and number of patients per group is listed below each graph. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. CCL17 CC chemokine ligand 17, IgE immunoglobulin E, IL interleukin, JP Japan, LDH lactate dehydrogenase, N number of patients with available data, TARC thymus- and activation-regulated chemokine
非 KM Figure
Fig. 6Change from baseline to week 16 in key biomarkers by racial subgroup analyzed in a mixed effect model, including adjusting for baseline IGA, age, and sex (see Appendix S1 in the Supporting Information for additional details). Predicted means at baseline and week 16 levels for serum LDH, CCL17/TARC, IL-22, and for S. aureus abundance on lesional skin are shown for placebo and tralokinumab groups. Error bars show 95% confidence intervals. BL baseline, CCL17 CC chemokine ligand 17, IL interleukin, JP Japan, LDH lactate dehydrogenase, TARC thymus- and activation-regulated chemokine, Wk16 week 16
非 KM Figure